During the last session, Aytu Biopharma Inc. (NASDAQ:AYTU)’s traded shares were 0.59 million, with the beta value of the company hitting -0.28. At the end of the trading day, the stock’s price was $3.70, reflecting an intraday loss of -3.39% or -$0.13. The 52-week high for the AYTU share is $14.00, that puts it down -278.38 from that peak though still a striking 11.89% gain since the share price plummeted to a 52-week low of $3.26. The company’s market capitalization is $91.09M, and the average intraday trading volume over the past 10 days was 0.29 million shares, and the average trade volume was 908.61K shares over the past three months.
Aytu Biopharma Inc. (AYTU) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. AYTU has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.49.
Aytu Biopharma Inc. (NASDAQ:AYTU) trade information
Aytu Biopharma Inc. (AYTU) registered a -3.39% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.39% in intraday trading to $3.70 this Friday, 09/03/21, hitting a weekly high. The stock’s 5-day price performance is 1.09%, and it has moved by -6.09% in 30 days. Based on these gigs, the overall price performance for the year is -64.08%. The short interest in Aytu Biopharma Inc. (NASDAQ:AYTU) is 1.95 million shares and it means that shorts have 1.32 day(s) to cover.
The consensus price target of analysts on Wall Street is $17.50, which implies an increase of 78.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11.00 and $24.00 respectively. As a result, AYTU is trading at a discount of -548.65% off the target high and -197.3% off the low.
Aytu Biopharma Inc. (AYTU) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to shrink -145.00% this quarter and then jump 62.50% in the quarter after that. In the rating firms’ projections, revenue will increase 126.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $20.9 million as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $23.8 million by the end of Sep 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $14.86 million and $13.52 million respectively. In this case, analysts expect current quarter sales to grow by 40.60% and then jump by 76.00% in the coming quarter.
While earnings are projected to return 91.30% in 2021.
Aytu Biopharma Inc. is due to release its next quarterly earnings between October 04 and October 08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aytu Biopharma Inc. (NASDAQ:AYTU)’s Major holders
Aytu Biopharma Inc. insiders own 7.28% of total outstanding shares while institutional holders control 28.36%, with the float percentage being 30.58%. Blackrock Inc. is the largest shareholder of the company, while 91 institutions own stock in it. As of Mar 30, 2021, the company held over 1.59 million shares (or 6.31% of all shares), a total value of $12.07 million in shares.
The next largest institutional holding, with 1.34 million shares, is of Armistice Capital, LLC’s that is approximately 5.33% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $10.2 million.
Also, the Mutual Funds coming in first place with the largest holdings of Aytu Biopharma Inc. (AYTU) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.6 million shares. This amounts to just over 2.36 percent of the company’s overall shares, with a $4.52 million market value. The same data shows that the other fund manager holds slightly less at 0.33 million, or about 1.30% of the stock, which is worth about $2.5 million.